Repository logo
  • Log In
    Log in via Symplectic to deposit your publication(s).
Repository logo
  • Communities & Collections
  • Research Outputs
  • Statistics
  • Log In
    Log in via Symplectic to deposit your publication(s).
  1. Home
  2. Faculty of Medicine
  3. Department of Medicine
  4. Department of Immunology and Inflammation
  5. Plasma lectin pathway complement proteins in patients with COVID-19 and renal disease
 
  • Details
Plasma lectin pathway complement proteins in patients with COVID-19 and renal disease
File(s)
fimmu-12-671052.pdf (5.44 MB)
Published version
Author(s)
Medjeral-Thomas, Nicholas
Troldborg, Anne
Hansen, Annette
Gisby, Jack
Clarke, Candice
more
Type
Journal Article
Abstract
We do not understand why non-white ethnicity and chronic kidney disease increase susceptibility to COVID-19. The lectin pathway of complement activation is a key contributor to innate immunity and inflammation. Concentrations of plasma lectin pathway proteins influence pathway activity and vary with ethnicity. We measured circulating lectin proteins in a multi-ethnic cohort of chronic kidney disease patients with and without COVID19 infection to determine if lectin pathway activation was contributing to COVID19 severity.
We measured 11 lectin proteins in serial samples from a cohort of 33 patients with chronic kidney impairment and COVID19. Controls were single plasma samples from 32 patients on dialysis and 32 healthy individuals.
We demonstrated multiple associations between recognition molecules and associated proteases of the lectin pathway and COVID-19, including COVID-19 severity. Some of these associations were unique to patients of Asian and White ethnicity.
Our novel findings demonstrate that COVID19 infection alters the concentration of plasma lectin proteins and some of these changes were linked to ethnicity. This suggests a role for the lectin pathway in the host response to COVID-19 and suggest that variability within this pathway may contribute to ethnicity-associated differences in susceptibility to severe COVID-19.
Date Issued
2021-04-29
Date Acceptance
2021-04-12
Citation
Frontiers in Immunology, 2021, 12
URI
http://hdl.handle.net/10044/1/87893
DOI
https://www.dx.doi.org/10.3389/fimmu.2021.671052
ISSN
1664-3224
Publisher
Frontiers Media
Journal / Book Title
Frontiers in Immunology
Volume
12
Copyright Statement
© 2021 Medjeral-Thomas, Troldborg, Hansen, Gisby, Clarke, Prendecki, McAdoo, Sandhu, Lightstone, Thomas, Willicombe, Botto, Peters, Pickering and Thiel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
License URL
https://creativecommons.org/licenses/by/4.0/
Sponsor
NIHR Health Services and Delivery Research (HS&DR) programme
United Kingdom Research and Innovation
Wellcome Trust
Medical Research Council (MRC)
UK Research and Innovation
Wellcome Trust
Grant Number
MR/S004068/1
097816/Z/11/ZR
MR/V027638/1
1257927
212252/Z/18/Z
Subjects
1107 Immunology
1108 Medical Microbiology
Publication Status
Published
Article Number
ARTN 671052
About
Spiral Depositing with Spiral Publishing with Spiral Symplectic
Contact us
Open access team Report an issue
Other Services
Scholarly Communications Library Services
logo

Imperial College London

South Kensington Campus

London SW7 2AZ, UK

tel: +44 (0)20 7589 5111

Accessibility Modern slavery statement Cookie Policy

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback